Actively Recruiting
A Nasal Treatment for COVID-19
Led by Indiana University · Updated on 2025-12-22
40
Participants Needed
1
Research Sites
143 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to test an investigational new inhaled medication called Optate.
CONDITIONS
Official Title
A Nasal Treatment for COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 to 60 years
- Mild COVID-19 upper respiratory tract infection symptoms for infected group
- Positive rapid COVID-19 test for infected group
- Ordinal Scale for Clinical Improvement (OSCI) less than 3 and/or fever over 100°F and/or nasal congestion for infected group
- Healthy controls must be 18 or older without mild COVID-19 symptoms
- Healthy controls must have a negative rapid COVID-19 test
- Healthy controls must have no known medical problems or medications that would make them unsuitable
You will not qualify if you...
- Forced Exhaled Volume (FEV1) less than 55% predicted on study day
- Ordinal Scale for Clinical Improvement (OSCI) 3 or higher
- Pregnancy
- Inability to follow commands or perform study procedures including spirometry and coordinated inhalation of study medication
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Riley Hospital for Children
Indianapolis, Indiana, United States, 46202
Actively Recruiting
Research Team
C
Charles Clem
CONTACT
K
Kenzie Mahan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here